Astellas Plans Five Cancer Drugs For Global Market By 2014
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma said it plans to become a major contributor of cancer drugs, beginning with five products it is developing for the global market over the next three years
Astellas Pharma said it plans to become a major contributor of cancer drugs, beginning with five products it is developing for the global market over the next three years. Astellas has applied in Japan for a drug to treat prostate cancer while concentrating on another prostate drug in the United States and Europe. It also is developing drugs for renal cell carcinoma and adrenal cortical cancers and acute myeloid leukemia, all in Phase III clinical trials. Astellas obtained the drugs when it acquired U.S.-based OSI Pharmaceuticals last year. (Click here for more - a subscription may be required) "Astellas Bolstering Cancer Therapies" - Nikkei (Japan) (6/28/11) |